Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.
Journal
Journal of Clinical Oncology
Series/Report No.
Journal of Clinical Oncology
Journal Volume
42
Journal Issue
16_suppl
Start Page
4034
End Page
4034
Date Issued
2024-01-01
Author(s)
Chau I.
Ajani, Jaffer A.
Kitagawa, Yuko
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Nathani, Rahee
Hu, Nan
Matsumura, Yasuhiro
Kato, Ken
Doki, Yuichiro
Type
journal article